Tuberculosis during lung cancer treatment-A case series

This study aimed to clarify the characteristics of patients with lung cancer undergoing treatment until the onset of tuberculosis. Between 2005 and 2019, patients who were admitted to Tokyo National Hospital due to tuberculosis during lung cancer treatment were examined retrospectively. There were 42 patients, and detailed medical information was obtained in 39 patients. The median age of the 39 patients were 75 years (range: 47–92 years), of which 33 were males and 36 were Japanese Baby Boomers or older. Regarding risk factors for developing tuberculosis, smoking was noted in 34 cases, oral corticosteroid use in 13, and previous tuberculosis in six. Thirty-seven patients had one risk factor and 19 had two or more risk factors, but diagnosis of latent tuberculosis infection (LTBI) was obtained in only one patients, and none had received LTBI treatment. The first-line treatment for lung cancer was resection in 13 cases, chemoradiotherapy in 6, chemotherapy in 10, radiation therapy in 3, laser therapy in 1, and best supportive care (BSC) alone in 6. At tuberculosis onset, BSC accounted for 17 cases, but other situations were considerably existed such as anticancer medication (12 cases), and observation after lung cancer treatment (10 cases). Tuberculosis occurred in various situations in elderly patients with lung cancer. It is critical to actively evaluate the risk of tuberculosis and consider LTBI screening and treatment.     

Pulmonary metastases in urogenital cancers: Surgical treatment and outcomes

IntroductionMetastasis is remaining one of the major problems in cancer treatment. Like many other malignancies, urogenital tumors originating from kidney, prostate, testes, and bladder tend to metastasize to the lungs.The aim of this retrospective study is to evaluate the operative results and prognosis of pulmonary metastasectomy in patients with primary urogenital tumors.MethodsThis study was approved by the local ethical committee. We retrospectively analyzed the surgical and oncological results of patients who underwent lung resections for urogenital cancer metastases in our department between 2002 and 2018. Demographic data and clinicopathological features were extracted from the medical records. Survival outcomes according to cancer subtypes and early postoperative results of VATS and thoracotomy were analyzed.Results22 out of 126 patients referred for pulmonary metastasectomy to our department had metastases from urogenital tumors. These patients consisted of 17 males and five females. Their metastasis originated from renal cell carcinoma (RCC; n = 9), bladder tumor (n = 7), testis tumors (n = 4), and prostate cancer (n = 2). There was no intraoperative complication. Postoperative complications were seen in 2 patients.ConclusionsAlthough pulmonary metastasectomy in various types of tumors is well known and documented, the data is limited for metastases of urogenital cancers in the literature. Despite the limitations of this study, we aim to document our promising results of pulmonary metastasectomy in patients with primary urogenital tumors and wanted to emphasize the role of minimally invasive approaches.     

阴道顺产与剖宫产对初产妇产后早期盆底功能的影响比较

目的研究阴道顺产与剖宫产对初产妇产后早期盆底功能的影响。方法选择2020年1月至12月在阳春市人民医院产科中心分娩的120例初产妇展开研究,按照分娩方式的不同分为对照组与观察组,每组各60例。对照组为阴道顺产,观察组采用剖宫产,两组均在产后第6周进行早期盆底功能检查,并进行盆底康复治疗,比较两组的治疗效果。结果观察组的尿失禁、阴道脱垂、子宫脱垂发生率低于对照组,差异有统计学意义(P<0.05);观察组治疗后的盆底肌力分级情况优于对照组,差异有统计学意义(P<0.05);观察组治疗后的膀胱颈与耻骨联合下缘水平线间的垂直距离(BSD)高于对照组,膀胱尿道后角(RA)、膀胱颈移动度(BND)低于对照组,差异均有统计学意义(P<0.05)。结论阴道顺产对于盆底功能及盆腔结构的不良影响大于剖宫产,盆底功能障碍性疾病发生率更高,而康复治疗可有效改善阴道顺产、剖宫产初产妇的盆底功能,剖宫产初产妇的盆底功能恢复更好。     

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

The 2021 WHO Classification of Thoracic Tumours was published earlier this year, with classification of lung tumors being one of the chapters. The principles remain those of using morphology first, supported by immunohistochemistry, and then molecular techniques. In 2015, there was particular emphasis on using immunohistochemistry to make classification more accurate. In 2021, there is greater emphasis throughout the book on advances in molecular pathology across all tumor types. Major features within this edition are (1) broader emphasis on genetic testing than in the 2015 WHO Classification; (2) a section entirely dedicated to the classification of small diagnostic samples; (3) continued recommendation to document percentages of histologic patterns in invasive nonmucinous adenocarcinomas, with utilization of these features to apply a formal grading system, and using only invasive size for T-factor size determination in part lepidic nonmucinous lung adenocarcinomas as recommended by the eighth edition TNM classification; (4) recognition of spread through airspaces as a histologic feature with prognostic significance; (5) moving lymphoepithelial carcinoma to squamous cell carcinomas; (6) update on evolving concepts in lung neuroendocrine neoplasm classification; (7) recognition of bronchiolar adenoma/ciliated muconodular papillary tumor as a new entity within the adenoma subgroup; (8) recognition of thoracic SMARCA4-deficient undifferentiated tumor; and (9) inclusion of essential and desirable diagnostic criteria for each tumor.     

Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force

IntroductionIn 2021, the U.S. Preventive Services Task Force (USPSTF) revised its lung cancer screening recommendations expanding its eligibility. As more smokers become eligible, cessation interventions at the point of screening could enhance the benefits. Here, we evaluate the effects of joint screening and cessation interventions under the new recommendations.MethodsA validated lung cancer natural history model was used to estimate lifetime number of low-dose computed tomography screens, percentage ever screened, lung cancer deaths, lung cancer deaths averted, and life-years gained for the 1960 U.S. birth cohort aged 45 to 90 years (4.5 million individuals). Screening occurred according to the USPSTF 2013 and 2021 recommendations with varying uptake (0%, 30%, 100%), with or without a cessation intervention at the point of screening with varying effectiveness (15%, 100%).ResultsScreening 30% of the eligible population according to the 2021 criteria with no cessation intervention (USPSTF 2021, 30% uptake, without cessation intervention) was estimated to result in 6845 lung cancer deaths averted and 103,725 life-years gained. These represent 28% and 34% increases, respectively, relative to screening according to the 2013 guidelines (USPSTF 2013, 30% uptake, without cessation intervention). Adding a cessation intervention at the time of the first screen with 15% effectiveness (USPSTF 2021, 30% uptake, with cessation intervention with 15% effectiveness) was estimated to result in 2422 additional lung cancer deaths averted (9267 total, ∼73% increase versus USPSTF 2013, 30% uptake, without cessation intervention) and 322,785 life-years gained (∼318% increase). Screening 100% of the eligible according to the 2021 guidelines with no cessation intervention (USPSTF 2021, 100% uptake, without cessation intervention) was estimated to result in 23,444 lung cancer deaths averted (∼337% increase versus USPSTF 2013, 30% uptake, without cessation intervention) and 354,330 life-years gained (∼359% increase). Adding a cessation intervention with 15% effectiveness (USPSTF 2021, 100% uptake, with cessation intervention with 15% effectiveness) would result in 31,998 lung cancer deaths averted (∼497% increase versus USPSTF 2013, 30% uptake, without cessation intervention) and 1,086,840 life-years gained (∼1309% increase).ConclusionsJoint screening and cessation interventions would result in considerable lung cancer deaths averted and life-years gained. Adding a one-time cessation intervention of modest effectiveness (15%) results in comparable life-years gained as increasing screening uptake from 30% to 100% because while cessation decreases mortality from many causes, screening only reduces lung cancer mortality. This simulation indicates that incorporating cessation programs into screening practice should be a priority as it can maximize overall benefits.     

小剂量克赛联合百令胶囊对微小病变型NS的疗效

目的 探讨小剂量克赛联合百令胶囊对微小病变型肾病综合征（NS）患者高凝血状态和免疫功能的影响。 方法 选取2017年4月～2020年5月于本院就诊的90例微小病变型NS患者，按随机数表法分为观察组（45例）和对照组（45例）。对照组服用百令胶囊，观察组同时应用小剂量克赛。观察两组患者临床疗效、肾功能指标变化、凝血指标变化、血液流变学指标变化、T淋巴细胞亚群及药物不良反应。 结果 治疗后，观察组治疗总有效率高于对照组（P＜0.05）；观察组肾功能损伤指标及24 h尿蛋白水平均低于对照组（P＜0.05）；观察组凝血相关时间指标水平高于对照组，凝血相关因子水平低于对照组（P＜0.05）；观察组血液流变学指标水平低于对照组（P＜0.05）；观察组外周T淋巴细胞亚群检测结果显示CD3+、CD4+、CD4+/CD8+水平高于对照组，CD8+水平低于对照组（均P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。 结论 小剂量克赛联合百令胶囊对微小病变型肾病综合征患者疗效确切，可减少患者肾功能损伤，调节血液高凝状态，降低血液粘稠度，提升人体免疫功能，且安全性较好。     

Patient and Procedure-related Characteristics Correlated With Severity of Hemoptysis Following Percutaneous Transthoracic Needle Biopsy: Results of a 10-year Retrospective Review

PurposeA risk of percutaneous transthoracic needle biopsy (PTNB) is hemoptysis, which can range from mild to life-threatening. The reported occurrence of hemoptysis is 1.7% to 14.5%, and the demographic, patient, and procedure characteristics have not been extensively described. The purpose of this study was to assess the associations of demographic, patient, and procedure characteristics with the severity of hemoptysis.Materials and MethodsA single institution, single group, retrospective, electronic medical record (EMR) review was performed on all hemoptysis events occurring between 2008 and 2018. Demographic, clinical, and procedure variables were extracted from EMRs. Outcome of hemoptysis events was graded using Common Terminology Criteria for Adverse Events (CTCAE). Mild-moderate and severe hemoptysis were defined as CTCAE classifications of 1-2 and 3-5, respectively. Associations were generated using logistic regressions and Likelihood Ratio Chi-Square tests.ResultsIn 10 years, 14,665 PTNB resulted in 231 hemoptysis events occurring in 229 patients; 12.7% (n = 29) of those were severe. The strongest and statistically significant variables associated with an increased likelihood of a severe event, if an event occurred, were cigarette pack years (OR = 1.02, 95% C.I. = 1.01-1.04, p = .020); history of chronic obstructive pulmonary disease (COPD) (OR = 3.68, 95% C.I. = 1.53-8.82, p = .003); core biopsy technique (OR = 8.13, 95% CI = 1.07, 61.40, p = .042), and larger diameter needle (20 g vs. 18 g: OR = 2.60, 95% CI 1.09, 6.17, p = .031).ConclusionsPTNB-associated hemoptysis was an uncommon event that was rarely life-threatening. The extent of the patient’s smoking history, the diagnosis of COPD, and core biopsy technique were associated with an increased likelihood of severe hemoptysis.     

女性生育力评估

随着人口老龄化和生育力的下降,我国放开了三孩政策,对有生育要求的夫妇进行生育力评估显得非常必要。女性生育力与年龄关系密切,还依赖于卵巢、输卵管、子宫等生殖器官。本文就影响女性生育力的因素进行介绍。